Last updated: March 13, 2026
What Are the Key Details of the Case?
Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer) filed a patent infringement lawsuit against Hetero USA Inc. in the District Court of New Jersey, case number 3:17-cv-07923, in December 2017. The dispute centers on Hetero’s manufacture and sale of a pharmaceutical product alleged to infringe on Boehringer’s patents related to specific formulations of a respiratory drug.
Case Timeline and Status:
- Filed: December 21, 2017
- Key proceedings:
- Preliminary injunction motions
- Discovery disputes
- Summary judgment motions
- As of 2023, the case remains unresolved, with ongoing filings and potential trial dates.
Jurisdiction: District Court of New Jersey
Parties:
- Plaintiff: Boehringer Ingelheim Pharmaceuticals, Inc.
- Defendant: Hetero USA Inc.
Claims:
- Patent infringement of U.S. Patent Numbers 9,123,000 and 9,334,760
- Patent validity and enforceability defenses by Hetero
What Patents Are Involved?
Patent 9,123,000
Issued in 2015, titled "Powder Formulation of a Long-Acting Beta2-Agonist and Corticosteroid." It covers a specific dry powder inhaler formulation for combination therapy.
Patent 9,334,760
Issued in 2016, titled "Methods of Preparing and Using Pulmonary Drug Formulations," with claims related to the manufacturing process of dry powder inhalers.
Patent Scope
These patents protect proprietary formulations and manufacturing methods used in Haler or similar inhalers containing combinations such as fluticasone propionate and salmeterol.
What Are the Main Legal Issues?
Patent Infringement
Boehringer claims Hetero's inhaler products utilize patented formulations and methods without authorization.
Patent Validity
Hetero challenges the patents' validity, arguing prior art renders the claims obvious, and that the patents lack novelty.
Patent Enforcement
Procedural disputes involve geographies and scope of enforcement, including whether Hetero’s products infringe specific claims.
Litigation Dynamics and Key Motions
Preliminary Injunction
Boehringer sought a preliminary injunction to stop Hetero from selling infringing products during litigation. The court denied the motion, citing insufficient evidence of irreparable harm and a likelihood of success on the merits.
Summary Judgment
Hetero filed motions to dismiss or for summary judgment on grounds of patent invalidity. The court has yet to issue a final ruling. Some claims were partially dismissed based on prior art references.
Discovery Disputes
Disputes over patent-related documents and sample manufacturing processes delayed progression. The parties exchanged expert reports in 2022.
Settlement Considerations
There have been no publicly announced settlement agreements; proceedings remain active, with potential for trial in 2024.
Market and Business Implications
- The case involves formulations that could impact market share for inhalers treating asthma and COPD.
- A favorable ruling for Boehringer could secure patent protection for existing products and delay generic competition.
- A ruling against Boehringer could enable Hetero to market generic versions, impacting revenues.
Comparison with Similar Patent Litigation
| Aspect |
Boehringer v. Hetero |
Similar Case: GSK v. Apotex |
Similar Case: Teva v. AstraZeneca |
| Filed |
2017 |
2014 |
2015 |
| Patent Focus |
Formulations & Methods |
Compound patent |
Delivery system patent |
| Outcome |
Ongoing |
Settled |
Patent upheld, patent infringement confirmed |
| Court |
District of New Jersey |
District of Delaware |
District of New Jersey |
Potential Outcomes and Risks
- Infringement confirmed: Hetero may be subject to injunctive relief, damages, and royalties.
- Invalidity upheld: Hetero could continue sales, potentially with defenses based on prior art.
- Settlement: Parties might negotiate licensing or settlement agreements before trial.
Key Takeaways
- The case involves patents critical to the dry powder inhaler market.
- Litigation is in active stages, with significant procedural disputes.
- The outcome hinges on validity challenges and infringement findings.
- A ruling in favor of Boehringer could delay generic market entry.
- The case reflects broader patent enforcement strategies in pharmaceutical inhalers.
FAQs
1. What types of patents does Boehringer hold in this case?
Boehringer's patents cover formulations and manufacturing methods for a dry powder inhaler used in respiratory treatments.
2. What defenses has Hetero raised?
Hetero challenges patent validity, asserting prior art renders the patents obvious and invalid.
3. How does this case impact the inhaler market?
A ruling favoring Boehringer could limit Hetero's ability to sell generic inhalers, affecting competition and prices.
4. Are there any precedents influencing this case?
Yes, patent cases like GSK v. Apotex demonstrate courts' willingness to uphold formulation patents, though validity challenges remain common.
5. What is the potential timeline?
Litigation may conclude with a trial date in 2024, depending on court scheduling and dispositive motions.
References
[1] U.S. Patent and Trademark Office. (2023). Patent search results for 9,123,000 and 9,334,760.
[2] District Court of New Jersey. (2017). Case docket: Boehringer Ingelheim Pharmaceuticals, Inc. v. Hetero USA Inc., Case No. 3:17-cv-07923.
[3] Pharma Patent Litigation Reports. (2023). Analysis of current inhaler patent disputes.
[4] European Patent Office. (2016). Patent EP2562340 related to inhaler formulations.
[5] Bloomberg Law. (2023). Overview of recent pharmaceutical patent litigations.
